Allergan
Executive Summary
Acquires Berkeley, Calif.-based Oculinum Inc., maker of Oculinum (botulinum toxin type A), an approved treatment for ocular muscle disorders. The acquisition will allow Allergan to manufacture the product and conduct research and development. Allergan became a distributor for Oculinum in December 1989. In February, Oculinum, Inc. filed a PLA for the botulinum toxin product in the treatment of spasmodic torticollis. Oculinum is currently in Phase III trials for juvenile cerebral palsy.